Search details
1.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood
; 142(23): 1960-1971, 2023 12 07.
Article
in English
| MEDLINE | ID: mdl-37647654
2.
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Intern Med J
; 53(9): 1678-1691, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37743239
3.
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Br J Haematol
; 196(5): 1209-1218, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34915592
4.
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
Blood
; 136(18): 2027-2037, 2020 10 29.
Article
in English
| MEDLINE | ID: mdl-32698195
5.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Article
in English
| MEDLINE | ID: mdl-32731259
6.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Blood
; 134(11): 851-859, 2019 09 12.
Article
in English
| MEDLINE | ID: mdl-31340982
7.
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol
; 20(2): 216-228, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30630772
8.
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Haematologica
; 102(2): 356-363, 2017 02.
Article
in English
| MEDLINE | ID: mdl-28143954
9.
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Br J Haematol
; 167(5): 618-25, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25142189
10.
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Neuro Oncol
; 26(4): 724-734, 2024 04 05.
Article
in English
| MEDLINE | ID: mdl-38037691
11.
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Blood Adv
; 8(7): 1639-1650, 2024 Apr 09.
Article
in English
| MEDLINE | ID: mdl-38315878
12.
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Blood Cancer J
; 14(1): 54, 2024 Mar 26.
Article
in English
| MEDLINE | ID: mdl-38531863
13.
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
J Clin Oncol
; 41(33): 5099-5106, 2023 Nov 20.
Article
in English
| MEDLINE | ID: mdl-37478390
14.
High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.
Br J Haematol
; 178(6): 991-994, 2017 09.
Article
in English
| MEDLINE | ID: mdl-27470657
15.
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
Blood Adv
; 6(4): 1296-1308, 2022 02 22.
Article
in English
| MEDLINE | ID: mdl-34724705
16.
Synchronous biphenotypic Richter syndrome with Epstein-Barr virus-positive nodal classical Hodgkin lymphoma and bone marrow diffuse large B-cell lymphoma.
Histopathology
; 69(4): 707-10, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-27079556
17.
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Blood Adv
; 5(12): 2577-2585, 2021 06 22.
Article
in English
| MEDLINE | ID: mdl-34152395
18.
Extent of radiological response does not reflect survival in primary central nervous system lymphoma.
Neurooncol Adv
; 3(1): vdab007, 2021.
Article
in English
| MEDLINE | ID: mdl-33615224
19.
Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
Neuro Oncol
; 23(8): 1315-1326, 2021 08 02.
Article
in English
| MEDLINE | ID: mdl-33560442
20.
Therapeutic drug monitoring for busulfan in plasma during conditioning chemotherapy for autologous stem cell transplantation in relapsed primary cerebral lymphoma.
Ther Drug Monit
; 32(3): 333-7, 2010 Jun.
Article
in English
| MEDLINE | ID: mdl-20386358